PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 487/04, A61K 31/505, C07D 401/12

A1

(11) International Publication Number: **WO 99/54333**

(43) International Publication Date: 28 October 1999 (28.10.99)

(21) International Application Number: PCT/IB99/00519

(22) International Filing Date: 25 March 1999 (25.03.99)

(30) Priority Data:

9808315.7	20 April 1998 (20.04.98)	GB
9814187.2	30 June 1998 (30.06.98)	GB

(71) Applicant *(for all designated States except GB US)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(71) Applicant *(for GB only)*: PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: BUNNAGE, Mark, Edward [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). MATHIAS, John, Paul [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). STREET, Stephen, Derek, Albert [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). WOOD, Anthony [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION



(IA)



(IB)

(57) Abstract

Compounds of formulae (IA) and (IB) wherein R^1 is C_1 to C_3 alkyl optionally substituted with phenyl, Het or a N–linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C_1 to C_4 alkoxy; halo; CN; CF_3; OCF_3 or C_1 to C_4 alkyl wherein said C_1 to C_4 alkyl group is optionally substituted by C_1 to C_4 haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R^2 is C_1 to C_6 alkyl and R^{13} is OR^3 or NR^5R^6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3',5'–monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).